肌层浸润性膀胱癌分子预后标记物研究进展

姚艳红; 王海涛

doi:10.3969/j.issn.1000-8179.2013.01.015

肌层浸润性膀胱癌分子预后标记物研究进展

doi: 10.3969/j.issn.1000-8179.2013.01.015

姚艳红,
王海涛^,

天津医科大学附属肿瘤医院介入治疗科, 天津市肿瘤防治中心重点实验室（天津市300060）

基金项目:

国家自然科学基金 81071787

天津市应用基础及前沿技术研究计划 08JCYBJC05300

详细信息

通讯作者:
王海涛 peterrock2000@126.com

计量
- 文章访问数: 8
- HTML全文浏览量: 24
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2012-08-16
- 修回日期: 2012-12-26

Progress in prognostic biomarkers of muscle-invasive bladder cancer

Yanhong YAO,
Haitao WANG^,

Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Can cer Prevention and Therapy, Tianjin 300060, China

Funds:

the National Natural Science Foundation of China 81071787

the Tianjin Municipal Research Program for Basic Science and Leading Technology 08JCYBJC05300

More Information

Corresponding author: Haitao Wang; E-mail: peterrock2000@126.com

摘要

摘要: 膀胱癌是泌尿系统常见肿瘤, 可分为非肌层浸润性膀胱癌、肌层浸润性膀胱癌和转移性膀胱癌。临床上患者多为非肌层浸润性膀胱癌, 易于复发, 复发后大多数细胞分化良好, 预后佳。但10%~30%患者肿瘤复发时转变为具有侵袭性的浸润性膀胱癌, 预后不良。目前临床上采用的分级分期方法很难准确预测具有复杂生物学行为的浸润性膀胱癌的预后。近年许多肿瘤标记物相继被发现并用于浸润性膀胱癌的诊断和预后判断。这些分子标记物不仅对浸润性膀胱癌患者预后的判断有提示作用, 同时决定着患者是否适合行保留膀胱的放化疗、新辅助化疗和以铂类为基础的辅助化疗等治疗方式。本文对影响浸润性膀胱癌预后的分子标记物进行综述。
- 肌层浸润性膀胱癌 /
- 分子标记物 /
- 预后 /
- 个体化治疗
Abstract: Bladder cancer is one of the most common urothelial tumors.Bladder cancer can be categorized as non–muscular invasive bladder cancer, muscular-invasive bladder cancer(MIBC), or metastatic bladder cancer.Patients with non-muscular invasive bladder cancer suffer from a high rate of recurrence and disease progression(10% to 30%).Current staging and grading systems fail to provide accurate prognoses of most MIBCs, which have complicated biological behaviors.Over the past few years, comprehensive developments on molecular mechanisms concerning the onset and progression of tumors have enabled the discovery of a host of tumor molecular markers that could be used for the diagnosis and prognosis of MIBC.These markers may not only provide suggestions on the prognoses of MIBC patients but also help determine appropriate therapeutic methods, such as bladder-conserved chemo-radiotherapy, neo-adjuvant chemotherapy, and cisplatin-based adjuvant chemotherapy.We aim to summarize the molecular markers that affect the prognosis of MIBCs in this review article.
- muscle-invasive bladder cancer /
- molecular markers /
- prognosis /
- individualized treatment

HTML全文

参考文献(20)

[1]	Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CACancer J Clin, 2011, 61(2): 69-90. doi: 10.3322/caac.20107
[2]	Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how farhave we come[J]CA Cancer J Clin, 2010, 60(4): 244-272.
[3]	Kim EJ, Yan C, Ha YS, et al. Analysis of hOGG1 genotype as aprognostic marker for muscle invasive bladder cancer: a novel ap proach using peptide nucleic acid-mediated, real-time PCR clamp ing[J]. Urol Oncol, 2012, 30(5): 673-679. doi: 10.1016/j.urolonc.2010.07.008
[4]	Ha YS, Yan C, Kim IY, et al. Tissue hOGG1 genotype predictsbladder cancer prognosis: a novel approach using a peptide nucleicacid clamping method[J]. Ann Surg Oncol, 2011, 18(6): 1775-1781. doi: 10.1245/s10434-010-1500-7
[5]	Ma L, Chu H, Wang M, et al. hOGG1 Ser326Cys polymorphismis associated with risk of bladder cancer in a Chinese population: Acase-control study[J]. Cancer Sci, 2012, 103(7): 1215-1220. doi: 10.1111/j.1349-7006.2012.02290.x
[6]	Wallerand H, Cai Y, Wainberg ZA, et al. Phospho-Akt pathwayactivation and inhibition depends on N-cadherin or phospho-EG FR expression in invasive human bladder cancer cell lines[J]. UrolOncol, 2010, 28(2): 180-188.
[7]	J ger T, Becker M, Eisenhardt A, et al. The prognostic value of cad herin switch in bladder cancer[J]. Oncol Rep, 2010, 23(4): 1125-1132.
[8]	Li C, Rock KL, Woda BA, et al. IMP3 is a novel biomarker for ad enocarcinoma in situ of the uterine cervix: an immunohistochemi cal study in comparison with p16(INK4a)expression[J]. ModPathol, 2007, 20(2): 242-247.
[9]	郑俊彪, 李建辉, 蒋海锋, 等. IMP3在膀胱癌中表达及与临床病理特征的关系[J]. 中国医师杂志, 2012, 14(4): 533-535. doi: 10.3760/cma.j.issn.1008-1372.2012.04.037
[10]	Szarvas T, vom Dorp F, Niedworok C, et al. High insulin-likegrowth factor mRNA-binding protein 3(IMP3)protein expres sion is associated with poor survival in muscle-invasive bladdercancer[J]. BJU Int, 2012, 110(6 Pt B): E308-317.
[11]	严东旺, 李大卫, 周崇治, 等. 胰岛素样生长因子ⅡmRNA结合蛋白-3在结肠癌中的表达及临床意义[J]. 中华实验外科杂志, 2010, 27(8): 1046-1048. doi: 10.3760/cma.j.issn.1001-9030.2010.08.012
[12]	Smith SC, Baras AS, Dancik G, et al. A 20-gene model for molecu lar nodal staging of bladder cancer: development and prospective assessment[J]. Lancet Oncol, 2011, 12(2): 137-143. doi: 10.1016/S1470-2045(10)70296-5
[13]	Kim WJ, Kim SK, Jeong P, et al. A four-gene signature predicts dis ease progression in muscle invasive bladder cancer[J]. Mol Med, 2011, 17(5-6): 478-485. doi: 10.2119/molmed.2010.00274
[14]	Choudhury A, Nelson LD, Teo MT, et al. MRE11 expression ispredictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer[J]. Cancer Res, 2010, 70(18): 7017-7026. doi: 10.1158/0008-5472.CAN-10-1202
[15]	Kawashima A, Nakayama M, Kakuta Y, et al. Excision repaircross-complementing group 1 may predict the efficacy of chemora diation therapy for muscle-invasive bladder cancer[J]. Clin CancerRes, 2011, 17(8): 2561-2569. doi: 10.1158/1078-0432.CCR-10-1963
[16]	Stordal B, Davey R. A systematic review of genes involved in the in verse resistance relationship between cisplatin and paclitaxel chemo therapy: role of BRCA1[J]. Curr Cancer Drug Targets, 2009, 9(3): 354-365. doi: 10.2174/156800909788166592
[17]	Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression andoutcome to neoadjuvant cisplatin-based chemotherapy in bladdercancer[J]. Ann Oncol, 2011, 22(1): 139-144. doi: 10.1093/annonc/mdq333
[18]	Hoffmann AC, Wild P, Leicht C, et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer re ceiving adjuvant chemotherapy[J]. Neoplasia, 2010, 12(8): 628-636. doi: 10.1593/neo.10402
[19]	Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ER CC1 as a novel prognostic marker in advanced bladder cancer pa tients receiving cisplatin-based chemotherapy[J]. Ann Oncol, 2007, 18(3): 522-528. doi: 10.1093/annonc/mdl435
[20]	Kim KH, Do IG, Kim HS, et al. Excision repair cross-complementa tion group 1(ERCC1)expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy[J]. APMIS, 2010, 118(12): 941-948. doi: 10.1111/j.1600-0463.2010.02648.x